XML 31 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies - 10-Q (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 18 Months Ended
Jun. 30, 2015
May 31, 2014
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Mar. 31, 2013
Dec. 31, 2015
Share-based Compensation                
Expected term (years)         6 years 3 months      
Net (Loss) Income Per Common Share                
Net loss     $ (7,854,693) $ (7,168,071) $ (23,481,241) $ (3,887,795)    
Basic and diluted net loss per common share (in dollars per share)     $ (0.34) $ (0.38) $ (1.14) $ (0.20)    
Basic and diluted weighted average common shares outstanding     23,049,347 19,025,623 20,638,129 18,999,705    
Level 1                
Fair Value Measurements                
Carrying value of cash held in money market fund     $ 44,100,000   $ 44,100,000     $ 45,500,000
Level 2                
Fair Value Measurements                
Assets measured at fair value levels 2 or 3     0   0     0
Liabilities measured at fair value levels 2 or 3     0   0     0
Level 3                
Fair Value Measurements                
Assets measured at fair value levels 2 or 3     0   0     0
Liabilities measured at fair value levels 2 or 3     $ 0   $ 0     $ 0
Maximum                
Share-based Compensation                
Expiration period         10 years      
Warrants [Member]                
Net (Loss) Income Per Common Share                
Anti-dilutive securities     555,412 590,595 555,412 590,595    
Stock Options and Restricted Stock Units [Member]                
Net (Loss) Income Per Common Share                
Anti-dilutive securities     2,815,166 2,250,008 2,815,166 2,250,008    
Pfizer | License Agreement | Up-Front Payment Arrangement                
Revenue Recognition                
Upfront payment revenue recognized             $ 22,500,000  
Recognition period of up-front payment             1 year 6 months  
Achievement Of Specified Development Milestone | Pfizer | License Agreement                
Revenue Recognition                
Milestone revenue $ 20,000,000 $ 15,000,000